8.71
0.09 (1.04%)
| Previous Close | 8.62 |
| Open | 8.62 |
| Volume | 625,128 |
| Avg. Volume (3M) | 2,750,140 |
| Market Cap | 608,080,768 |
| Price / Sales | 7.11 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2025 |
| Operating Margin (TTM) | -276.53% |
| Diluted EPS (TTM) | -5.18 |
| Quarterly Revenue Growth (YOY) | 1,391.60% |
| Current Ratio (MRQ) | 3.58 |
| Operating Cash Flow (TTM) | -282.68 M |
| Levered Free Cash Flow (TTM) | -201.84 M |
| Return on Assets (TTM) | -55.01% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Phathom Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.00 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.28% |
| % Held by Institutions | 84.77% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Catalys Pacific, Llc | 31 Mar 2025 | 1,167,114 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Needham, 221.47%) | Buy |
| Median | 20.00 (129.62%) | |
| Low | 17.00 (Craig-Hallum, 95.18%) | Buy |
| Average | 21.67 (148.79%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 8.86 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 09 Jun 2025 | 17.00 (95.18%) | Buy | 8.83 |
| HC Wainwright & Co. | 09 Jun 2025 | 20.00 (129.62%) | Buy | 8.83 |
| Needham | 06 Jun 2025 | 28.00 (221.47%) | Buy | 8.92 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |